"Adrenergic Agonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs that bind to and activate adrenergic receptors.
| Descriptor ID |
D000322
|
| MeSH Number(s) |
D27.505.519.625.050.100 D27.505.696.577.050.100
|
| Concept/Terms |
Adrenergic Agonists- Adrenergic Agonists
- Agonists, Adrenergic
- Receptor Agonists, Adrenergic
- Adrenomimetics
- Adrenergic Agonist
- Agonist, Adrenergic
- Adrenergic Receptor Agonists
- Agonists, Adrenergic Receptor
- Adrenergic Receptor Agonist
- Agonist, Adrenergic Receptor
- Receptor Agonist, Adrenergic
|
Below are MeSH descriptors whose meaning is more general than "Adrenergic Agonists".
Below are MeSH descriptors whose meaning is more specific than "Adrenergic Agonists".
This graph shows the total number of publications written about "Adrenergic Agonists" by people in this website by year, and whether "Adrenergic Agonists" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 0 | 1 | 1 |
| 2004 | 0 | 1 | 1 |
| 2006 | 0 | 1 | 1 |
| 2014 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Adrenergic Agonists" by people in Profiles.
-
Autoimmune basis for postural tachycardia syndrome. J Am Heart Assoc. 2014 Feb 26; 3(1):e000755.
-
Involvement of G protein-coupled receptor kinase (GRK) 3 and GRK2 in down-regulation of the alpha2B-adrenoceptor. J Pharmacol Exp Ther. 2006 Jun; 317(3):1027-35.
-
Simultaneous alpha2B- and beta2-adrenoceptor activation sensitizes the alpha2B-adrenoceptor for agonist-induced down-regulation. J Pharmacol Exp Ther. 2004 Nov; 311(2):794-802.
-
Conditioning of beta(1)-adrenoceptor effect via beta(2)-subtype on L-type Ca(2+) current in canine ventricular myocytes. Am J Physiol Heart Circ Physiol. 2000 Sep; 279(3):H1329-37.